Profile data is unavailable for this security.
About the company
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
- Revenue in USD (TTM)38.34m
- Net income in USD-149.65m
- Incorporated2003
- Employees172.00
- LocationMerus NVUppsalalaan 17, 3rd & 4th floorUTRECHT 3584 CTNetherlandsNLD
- Phone+31 850162500
- Websitehttps://merus.nl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.40bn | 526.00 | -- | 2.31 | -- | 45.63 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.40bn | 1.45k | -- | 6.68 | -- | 4.57 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.41bn | 919.00 | -- | 4.29 | -- | 8.68 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.41bn | 445.00 | -- | 3.95 | -- | 33.81 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.55bn | 50.00 | -- | 4.63 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.57bn | 610.00 | -- | 5.52 | 287.07 | 3.15 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Merus NV | 38.34m | -149.65m | 2.59bn | 172.00 | -- | 7.40 | -- | 67.46 | -2.72 | -2.72 | 0.7031 | 5.95 | 0.0917 | -- | 1.21 | 222,889.50 | -35.78 | -29.35 | -43.82 | -35.36 | -- | -- | -390.36 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.62bn | 284.00 | 77.01 | 16.39 | 63.43 | 9.07 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 2.63bn | 253.00 | -- | 3.16 | -- | 241.69 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.69bn | 91.00 | -- | 3.24 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Arcellx Inc | 131.66m | -50.54m | 2.71bn | 130.00 | -- | 5.43 | -- | 20.57 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Azenta Inc | 651.76m | -152.26m | 2.71bn | 3.40k | -- | 1.24 | -- | 4.16 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.72bn | 570.00 | -- | 6.61 | -- | 9.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 2.75bn | 375.00 | -- | 1.89 | -- | 9.30 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.75bn | 1.26k | -- | 3.82 | -- | 4.39 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Guardant Health Inc | 603.73m | -460.90m | 2.75bn | 1.78k | -- | 40.15 | -- | 4.56 | -3.92 | -3.92 | 5.17 | 0.5607 | 0.3754 | 4.37 | 7.03 | 339,362.00 | -28.66 | -22.26 | -33.02 | -24.59 | 60.37 | 64.62 | -76.34 | -97.07 | 5.66 | -59.55 | 0.9435 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
Data as of May 23 2024. Currency figures normalised to Merus NV's reporting currency: US Dollar USD
37.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Commodore Capital LPas of 31 Mar 2024 | 4.36m | 7.53% |
| RTW Investments LPas of 31 Mar 2024 | 4.11m | 7.10% |
| Federated Global Investment Management Corp.as of 31 Mar 2024 | 2.25m | 3.89% |
| Samlyn Capital LLCas of 31 Mar 2024 | 2.08m | 3.59% |
| Franklin Advisers, Inc.as of 31 Mar 2024 | 1.86m | 3.22% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.66m | 2.87% |
| Lynx1 Capital Management LPas of 31 Mar 2024 | 1.51m | 2.61% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 1.25m | 2.16% |
| Driehaus Capital Management LLCas of 31 Mar 2024 | 1.23m | 2.12% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.19m | 2.05% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
